Goal and Learning Outcomes
Upon completion of this activity, participants should be better able to:
- Describe patient evaluation, diagnostic approach, and risk stratification in primary biliary cholangitis.
- Review strategies of using UDCA and OCA in practice as well as guideline update on OCA and fibrates.
- Assess the mechanisms of investigational therapies, data from Phase 2 studies, and trials available.
Kris V. Kowdley, MD
Dr. Kris Kowdley is the Director of the Liver Care Network and Organ Care Research at Swedish Medical Center. He is on clinical faculty at Washington State University, Elson S. Floyd College of Medicine.
Dr. Kowdley is an internationally recognized leader in the field of hepatology. He has conducted both translational and clinical research and authored more than 400 articles and book chapters. He contributed to the development of breakthrough therapies that meet the unmet need of patients with liver disease including primary biliary cholangitis.
Raj K. Vuppalanchi, MD
Dr. Raj Vuppalanchi is the Director of Clinical Hepatology at IU Health and Professor of Medicine at Indiana University School of Medicine.
Dr. Vuppalanchi is trained in both gastroenterology-hepatology and clinical pharmacology. He has published extensively on various aspects of liver disease that include novel tools in disease evaluation and new therapies in management. He is the lead investigator of a clinical trial that studied a PPAR agonist in the treatment of primary biliary cholangitis.
This course is being provided by a Relias LLC strategic partner. Consumption of this course will take place on the partners site and courses provided in this manner are not accredited by Relias LLC.